Close

Pfizer looks past COVID with $43 billion deal for cancer drug maker Seagen Mar 13, 2023 06:54AM
Seagen (SGEN) Stock Drops on Report Talks with Merck (MRK) are Stalling Over Price Aug 26, 2022 09:13AM
Needham & Company Reiterates Buy Rating on Seagen (SGEN), Latest EV-103 Data is Very Encouraging Feb 15, 2022 06:23AM
Seagen (SGEN) Stock Plunges on Weak Outlook and Q4 Miss, Analysts Lower Price Targets Feb 10, 2022 07:14AM
Needham & Company Lowers PT on Seagen (SGEN) to $180 on Weak Earnings, Reiterates Confidence in Long-Term Growth Prospects Feb 10, 2022 06:11AM
View Older Stories

Sep 14, 2020 09:30AM Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...)
Jun 30, 2020 07:28AM Seattle Genetics (SGEN) PT Raised to $188 at Needham & Company on Drug Platform Expansion
Jun 30, 2020 05:43AM Seattle Genetics (SGEN) PT Raised to $188 at Needham & Company
Apr 8, 2020 08:00AM Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference
Dec 19, 2019 02:27PM Seattle Genetics (SGEN) PT Raised to $135 at Needham & Company, Following Approval of Bladder Cancer Drug
Oct 30, 2019 07:51AM Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
Oct 21, 2019 12:31PM Seattle Genetics (SGEN) PT Raised to $121 at Needham & Company
Oct 21, 2019 09:21AM Pre-Open 10/21: (MDR) (OPK) (FSCT) Higher (KMT) (IPHS) (BA) Lower (more...)
Sep 30, 2019 07:04AM Seattle Genetics (SGEN) Reports Strong Data at ESMO
Feb 8, 2019 01:50PM Seattle Genetics (SGEN) PT Raised to $81 at Needham & Company
Jul 27, 2018 12:22PM Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
Jun 19, 2017 12:30PM Needham & Company Reiterates Buy Rating and $72 PT on Seattle Genetics (SGEN) Following Discontinuation of Vadastuximab Development; 'Buy on Weakness Ahead of ESCHELON-1'
Dec 27, 2016 10:45AM Needham & Company Tells Seattle Genetics (SGEN) Investors Not to Overreact About Vadastuximab Clinical Hold
Aug 1, 2016 12:12PM Streetinsider.com's Hot Lunchtime Reads 8/1: (AXTA) (SCTY) (XON) (SGEN)
Jun 28, 2016 07:52AM Seattle Genetics (SGEN): Adcetris Could Become a Blockbuster - Needham
Jun 24, 2016 11:13AM Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
Dec 8, 2015 08:15AM Seattle Genetics (SGEN) Delivers at ASH - Needham & Company
Oct 30, 2015 01:12PM Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
Sep 14, 2015 08:00AM Seattle Genetics Announces Exercise of Over-Allotment Option
Sep 11, 2015 07:18AM Seattle Genetics (SGEN) Prices 11.7M Common Stock Offering at $41/Share
Sep 10, 2015 06:19PM Seattle Genetics Announces Pricing of Public Offering of Common Stock
Aug 18, 2015 11:12AM Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval
Sep 29, 2014 11:00AM Needham & Company Maintians Bullish Stance on Seattle Genetic (SGEN) Amid AETHERA Data
May 6, 2014 11:09AM Notable Analyst Rating Changes 05/06: (VLO) (BBG) (SCHW) Upgraded; (TGT) (DCT) (FN) Downgraded
Feb 12, 2014 09:35AM Pre-Open Stock Movers 2/12: (OC) (CSTE) (TRIP) Higher; (VTUS) (RLOC) (PRGN) Lower (more...)
Feb 12, 2014 07:43AM Needham & Company Upgrades Seattle Genetics (SGEN) to Buy; Could Be Next Large Cap Drug Co.
Feb 13, 2013 12:15PM StreetInsider.com Notable Analyst Rating Changes 02/13: (GRPN) (NNA) (UTIW) Upgraded; (FOSL) (SGEN) (SAPE) Downgraded
Feb 13, 2013 07:54AM Needham & Company Downgrades Seattle Genetics (SGEN) to Hold
Jul 18, 2012 01:06PM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
Jun 8, 2012 02:53PM Notable 52-Week Highs and Lows of the Day 06/08: (SGEN) (NEON) (DG) High; (ANR) (ACI) (AUO) Low
Jun 8, 2012 07:50AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
Feb 14, 2012 08:31AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Impressive First Full Quarter of Adcetris Sales
Jan 6, 2012 10:44AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2012 Preview
Dec 23, 2011 07:35AM Needham & Company 2012 Biotech Preview
Dec 14, 2011 07:40AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Adcetris Data in Combination with AVD Supportive of Potential Role in Front Line Therapy
Nov 11, 2011 11:26AM Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
Nov 11, 2011 09:12AM Needham & Company Assumes Coverage on Seattle Genetics (SGEN) at Buy; 3Q11 Review and ASH Meeting Preview
Sep 16, 2011 11:01AM Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded
Aug 22, 2011 03:06PM Needham & Company Reiterates a 'Buy' on Seattle Genetics; As the School Year Begins, So Does Commercial Life for SGEN
Jul 12, 2011 03:33PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS
Jun 8, 2011 08:07AM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); ASCO Meeting Highlights Include Durable Responses Induced By B. Vedotin
May 19, 2011 08:24AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
May 6, 2011 09:45AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising PT
Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
Feb 9, 2011 08:45AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Trials/Other Pipeline Data Set the 2011 Mission
Feb 1, 2011 04:40PM Seattle Genetics (SGEN) To Offer Common Shares
Jan 5, 2011 08:26AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2011 May Be a Transformational Year
Dec 6, 2010 07:59AM Needham & Company reiterates a 'Buy' on Seattle Genetics (SGEN); B is for BLA, and Ved is for Very Exemplary Data - Pivotal Trial Results
Nov 2, 2010 08:17AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN)
Sep 27, 2010 11:13AM Needham & Company Lifts Target On Seattle Genetics (SGEN) Following Positive Data
View Older Stories